New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
14:55 EDTIDIX Idenix downgraded to Hold from Buy at Maxim
Maxim believes Idenix is likely to drop both IDX184 and IDX368 and will focus IDX719. Price target lowered to $5 from $11.
News For IDIX From The Last 14 Days
Check below for free stories on IDIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
07:23 EDTIDIXEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
11:47 EDTIDIXIdenix price target raised to $9 from $6 at Leerink
Leerink raised Idenix's price target to $9 from $6 citing positive IDX21437 data.
April 7, 2014
16:28 EDTIDIXOn The Fly: Closing Wrap
Subscribe for More Information
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-nave, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-nave, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use